Thomas Maciel Lester

US Patent:

7485314, Feb 3, 2009

Filed:

May 6, 2002

Appl. No.:

10/141668

Inventors:

Emil D. Kakkis - Novato CA, US
Merry Passage - Torrance CA, US
Thomas Lester - Harbor City CA, US
Rebecca Yang - Los Angeles CA, US
Christopher Tanaka - Gardena CA, US

Assignee:

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center - Torrance CA

International Classification:

A61K 45/00

US Classification:

4242781, 424 941

Abstract:

Antigen specific immune tolerance is induced in a mammalian host by administration of a toleragen in combination with a regimen of immunosuppression. The methods optionally include a preceding conditioning period, where immunosuppressive agents are administered in the absence of the toleragen. After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen. Optimally, the toleragen will have high uptake properties that allow uptake in vivo at low concentrations in a wide variety of tolerizing cell types.

US Patent:

7883707, Feb 8, 2011

Filed:

Mar 27, 2009

Appl. No.:

12/412986

Inventors:

Emil D. Kakkis - Novato CA, US
Thomas Lester - Harbor City CA, US
Merry Passage - Torrance CA, US
Christopher Tanaka - Gardena CA, US
Rebecca Yang - Los Angeles CA, US

International Classification:

A61K 39/385

US Classification:

4241931, 4241981

Abstract:

Antigen specific immune tolerance is induced in a mammalian host by administration of a toleragen in combination with a regimen of immunosuppression. The methods optionally include a preceding conditioning period, where immunosuppressive agents are administered in the absence of the toleragen. After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen. Optimally, the toleragen will have high uptake properties that allow uptake in vivo at low concentrations in a wide variety of tolerizing cell types.

US Patent:

20040009906, Jan 15, 2004

Filed:

May 5, 2003

Appl. No.:

10/429314

Inventors:

Emil Kakkis - Novato CA, US
Thomas Lester - Harbor City CA, US
Merry Passage - Torrance CA, US
Christopher Tanaka - Gardena CA, US
Rebecca Yang - Los Angeles CA, US

International Classification:

A61K038/13
A61K039/00

US Classification:

514/011000, 424/185100

Abstract:

Antigen specific immune tolerance is induced in a mammalian host by administration of a toleragen in combination with a regimen of immunosuppression. The methods optionally include a preceding conditioning period, where immunosuppressive agents are administered in the absence of the toleragen. After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen. Optimally, the toleragen will have high uptake properties that allow uptake in vivo at low concentrations in a wide variety of tolerizing cell types.

US Patent:

20050191309, Sep 1, 2005

Filed:

Nov 3, 2004

Appl. No.:

10/980648

Inventors:

Emil Kakkis - Novato CA, US
Thomas Lester - Cardiff CA, US
Merry Passage - Torrance CA, US
Christopher Tanaka - Gardena CA, US
Rebecca Yang - Los Angeles CA, US

International Classification:

A61K039/00
A61K038/13
A61K031/7024
A61K031/522

US Classification:

424184100, 514011000, 514263310, 514023000

Abstract:

Antigen specific immune tolerance is induced in a mammalian host by administration of a toleragen in combination with a regimen of immunosuppression. The methods optionally include a preceding conditioning period, where immunosuppressive agents are administered in the absence of the toleragen. After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen. Optimally, the toleragen will have high uptake properties that allow uptake in vivo at low concentrations in a wide variety of tolerizing cell types.